Study of the Expression of miR-4270 in Plasma of Patients with Breast Invasive Ductal Carcinoma

Document Type : Research Article


Department of Biological Sciences, School of Natural Sciences, University of Tabriz


Detection of tumor-specific microRNAs (miRs) in the blood of cancer patients may provide a unique and valuable biomarker for diagnosis and prognosis. The aim of this study was to investigate whether plasma levels of microRNA-4270 could serve as a potential marker for breast invasive ductal carcinoma. A total of 40 breast cancer patients and 28 controls were recruited in this study. Total RNA was extracted from plasma samples andmiR-4270 expression was evaluated by real-time polymerase chain reaction (PCR). The correlation between miR-4270 expression and clinicopathological characteristics were also studied. Our data showed that plasma miR-4270 is significantly up-regulated in patients compared to control group (P-value=0.00). In addition, data analysis illustrated a correlation between low plasma levels of miR-4270 and larger tumor size, lymph node metastasis and higher stages of malignancy (P-value > 0.05). The area under the curve of the ROC revealed thatmiR-4270 expression was not able to distinguish between tumor plasmas and nontumoral specimens. Current work shows preliminary data on the expression profile of-4270 in plasma of breast cancer patients. However, further studies are required to fully elucidate the role of circulating mix-4270 in breast ductal carcinoma.


Anker P, Mulcahy H, Chen XQ, Straun M. 1999. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer and Metastasis Rev 18(1): 65-73.
Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, Saghir NS. 2013. Epidemiology and prognosis of breast cancer in young women. J Thor Dis 5(1): 2-8.
Croce CM. 2009. Causes and consequences of microRNA dysregulation in cancer. Nate Rev Genetics 10(10): 704-714.
Fan M, Krutilina R, Sun J, Sethuraman A, Yang CH, Wu ZH, Yue J, Pfeffer LM. 2013. Comprehensive analysis of microRNA (miRNA) targets in breast cancer cells. J Biol Chem 288(38): 27480-27493.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12): 2893-2917.
Hamam R, Ali AM, Alsaleh KA, Kassem M, Alfayez M, Aldahmash A, Alajez NM. (2016). microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. Sci Rep 6: 25997.
Kruk J.2014. Lifestyle components and primary breast cancer prevention. Asian Pac J Cancer Prev 15(24): 10543-10555.
Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL. 2008. Detection of elevated levels of tumour associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141: 672–675.
Ling H, Fabbri M, Calin GA. 2013. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 12(11): 847-865.
MacFarlane LA, Murphy P. 2010. MicroRNA: biogenesis, function and role in cancer. Curr Genomics 11(7): 537-561.
Mar-Aguilar F, Rodríguez-Padilla C, Reséndez-Pérez D. 2014. Use of serum-circulating miRNA profiling for the identification of breast cancer biomarkers. Methods Mol Biol 1165: 71-80.
Moore MA, Yoo KY, Tuncer M, Sobue T. 2010. Overview of players and information in the cancer epidemiology and control world in Asia,  Asian Pac J Cancer Prev 11(2): 1-10.
Roth C, Rack B, Müller V, Janni W, Pantel K, Schwarzenbach H. 2010. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 12(6): R90.
Schwarzenbach H, Alix-Panabières C, Müller I, Letang N, Vendrell JP, Rebillard X, Pantel K. 2009. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 15(3): 1032-1038.
Tafrihi M, Hasheminasab E. 2019. MiRNAs: biology, biogenesis, their web-based tools, and databases. MicroRNA 8: 1-24.
Tuna M, Machado AS, Calin GA. 2016. Genetic and epigenetic alterations of microRNAs and implications for human cancers and other diseases. Genes Chromosomes Cancer 55(3): 193-214.
Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, Qin YW, Jing Q. 2010. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31(6): 659-666.
Zhang ZJ, Ma SL. 2012. miRNAs in breast cancer tumorigenesis. Oncol Rep 27(4): 903-910.